Advertisement
Advertisement
U.S. markets open in 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement
WEF 2022

Yahoo Finance is in Davos! Get the latest updates here

Assembly Biosciences, Inc. (ASMB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6300-0.0200 (-1.21%)
At close: 04:00PM EDT
1.7000 +0.07 (+4.29%)
After hours: 07:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close1.6500
Open1.6700
Bid1.5200 x 800
Ask1.7000 x 1000
Day's Range1.6250 - 1.6800
52 Week Range1.3200 - 4.6900
Volume66,493
Avg. Volume441,257
Market Cap78.593M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-2.7700
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ASMB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Assembly Biosciences, Inc.
    ENTA: Lowering target price to $52.00ENANTA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $52.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022. John McHutchison, AO, MD, chief executive officer and president of Assembly Bio, said, “We are excited to expand our pipeline with the introducti

  • GlobeNewswire

    Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced a grant of stock options to one new employee to purchase 19,000 shares of the Company’s common stock with an exercise price of $2.06 per share, the closing price of Assembly Bio’s common stock on April 1, 2022. The stock options were granted a

  • Simply Wall St.

    Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Advertisement
Advertisement